EVOK 📈 Evoke Pharma - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30049G2030
EVOK: Gastroparesis Treatment, Gastrointestinal Disorder Medication, Nasal Sprays
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. Web URL: https://www.evokepharma.com
Additional Sources for EVOK Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EVOK Stock Overview
| Market Cap in USD | 7m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2013-09-25 |
EVOK Stock Ratings
| Growth 5y | -96.0% |
| Fundamental | -39.8% |
| Dividend | - |
| Rel. Strength Industry | -3663 |
| Analysts | 4/5 |
| Fair Price Momentum | 2.02 USD |
| Fair Price DCF | - |
EVOK Dividends
No Dividends PaidEVOK Growth Ratios
| Growth Correlation 3m | -56.1% |
| Growth Correlation 12m | -82% |
| Growth Correlation 5y | -95.5% |
| CAGR 5y | -53.74% |
| CAGR/Mean DD 5y | -0.70 |
| Sharpe Ratio 12m | -0.56 |
| Alpha | -81.58 |
| Beta | 0.78 |
| Volatility | 94.61% |
| Current Volume | 8.6k |
| Average Volume 20d | 35.8k |
What is the price of EVOK stocks?
As of January 10, 2025, the stock is trading at USD 4.41 with a total of 8,585 shares traded.
Over the past week, the price has changed by -1.34%, over one month by +3.25%, over three months by -14.70% and over the past year by -59.17%.
As of January 10, 2025, the stock is trading at USD 4.41 with a total of 8,585 shares traded.
Over the past week, the price has changed by -1.34%, over one month by +3.25%, over three months by -14.70% and over the past year by -59.17%.
Is Evoke Pharma a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Evoke Pharma (NASDAQ:EVOK) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -39.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EVOK as of January 2025 is 2.02. This means that EVOK is currently overvalued and has a potential downside of -54.2%.
Probably not. Based on ValueRay Fundamental Analyses, Evoke Pharma (NASDAQ:EVOK) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -39.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EVOK as of January 2025 is 2.02. This means that EVOK is currently overvalued and has a potential downside of -54.2%.
Is EVOK a buy, sell or hold?
Evoke Pharma has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy EVOK.
Evoke Pharma has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy EVOK.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for EVOK stock price target?
According to ValueRays Forecast Model, EVOK Evoke Pharma will be worth about 2.2 in January 2026. The stock is currently trading at 4.41. This means that the stock has a potential downside of -50.57%.
According to ValueRays Forecast Model, EVOK Evoke Pharma will be worth about 2.2 in January 2026. The stock is currently trading at 4.41. This means that the stock has a potential downside of -50.57%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 18 | 308.2% |
| Analysts Target Price | 7 | 58.7% |
| ValueRay Target Price | 2.2 | -50.6% |